Maze Therapeutics, Inc.
MAZEFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Maze Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 2 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 24, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Maze Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-05-26 · Coloma Jason V: Larger than 53 of the 57 other insider sales of Common Stock on file. SEC filing
- 2026-03-10 · Bernstein Harold: Larger than 56 of the 57 other insider sales of Common Stock on file. SEC filing
- 2026-01-07 · Sohn Catherine A.: Larger than 54 of the 57 other insider sales of Common Stock on file. SEC filing
- 2026-01-07 · Bernstein Harold: Larger than 52 of the 57 other insider sales of Common Stock on file. SEC filing
- 2025-12-29 · Bernstein Harold: Larger than 55 of the 57 other insider sales of Common Stock on file. SEC filing
- 2025-12-29 · Dandekar Atul: Larger than all 57 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-23 | Coloma Jason V · Chief Executive Officer | Common Stock | S — Open market or private sale | −23,865 | 26.05 | SEC filing |
| 2026-06-22 | Coloma Jason V · Chief Executive Officer | Common Stock | S — Open market or private sale | −2,040 | 26.00 | SEC filing |
| 2026-06-22 | Coloma Jason V · Chief Executive Officer | Common Stock | S — Open market or private sale | −1,953 | 26.00 | SEC filing |
| 2026-06-01 | Coloma Jason V · Chief Executive Officer | Common Stock | S — Open market or private sale | −6,090 | 26.20 | SEC filing |
| 2026-06-01 | Bernstein Harold · President, R&D & CMO | Common Stock | S — Open market or private sale | −1,600 | 26.36 | SEC filing |
| 2026-06-01 | Bernstein Harold · President, R&D & CMO | Common Stock | S — Open market or private sale | −13,253 | 25.57 | SEC filing |
| 2026-06-01 | Coloma Jason V · Chief Executive Officer | Common Stock | S — Open market or private sale | −553 | 26.24 | SEC filing |
| 2026-05-29 | Dandekar Atul · CSBO | Common Stock | S — Open market or private sale | −7,500 | 26.34 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-08 | SPIEGELMAN DANIEL K · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +18,000 | SEC filing |
| 2026-06-08 | SCHELLER RICHARD H · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +18,000 | SEC filing |
| 2026-06-08 | Lim Jonathan E · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +18,000 | SEC filing |
| 2026-06-08 | Hoppenot Herve · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +18,000 | SEC filing |
| 2026-06-08 | Andrews Nancy C · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +18,000 | SEC filing |
| 2026-06-08 | HOMCY CHARLES J · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +18,000 | SEC filing |
| 2026-06-01 | Bernstein Harold · President, R&D & CMO | Common Stock | M — Exercise or conversion of derivative security | +14,853 | SEC filing |
| 2026-06-01 | Bernstein Harold · President, R&D & CMO | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −14,853 | SEC filing |
Showing 8 of 22 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-11-19 | HOMCY CHARLES J · Director | Common Stock | J — Other acquisition or disposition | +1,489 | SEC filing |
| 2025-11-04 | TRV GP IV, LLC · 10% owner | Common Stock | J — Other acquisition or disposition | −1,600,000 | SEC filing |
| 2024-12-09 | HOMCY CHARLES J · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −5,704 | SEC filing |
| 2024-12-09 | Lim Jonathan E · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −5,704 | SEC filing |
| 2024-12-09 | HOMCY CHARLES J · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −45,638 | SEC filing |
| 2024-12-09 | HOMCY CHARLES J · Director | Stock Option (Right to Buy) | D — Disposition to the issuer | −46,675 | SEC filing |
Showing 6 of 6 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.